Biologics

Pete O'Heeron is the founder and CEO of SpinalCyte.

Aziyo Biologics will exclusively distribute its bone repair product ViBone through RTI Surgical in the U.S.

Asterias Biotherapeutics provided an update from its ongoing phase 1/2a clinical trial of a stem cell treatment for severe spinal cord injury.

Ortho Regenerative Technologies earned extensions of expiry dates on certain warrants.

Johnson City, Tenn.-based Appalachian Orthopedics now offers cartilage restoration procedures.

Tom Cycyota is the president and CEO of AlloSource.

BioRestorative Therapies develops stem cell treatments for chronic back pain caused by disc degeneration.

Cerapedics began its investigational device exemption clinical trial for its P-15L Peptide Enhanced Bone Graft.

The global spine biologics market is projected to grow at a 4.4 percent compound annual growth rate, from $226 billion in 2018 to $280 billion by 2023, according to a Market Data Forecast report.

Orthopedic company 206 Ortho secured a patent for a new biocompatible composite designed to repair load-bearing bone and resorb without leaving a trace.